Neurocrine Biosciences Inc (NBIX.OQ)
4 Dec 2013
|Market Cap (Mil.):||$662.66|
|Shares Outstanding (Mil.):||67.34|
(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s)
Sept. 10 - Some U.S. stocks to watch on Tuesday:
- Neurocrine Biosciences Inc said a lower dose of its experimental drug to treat a rare movement disorder did not meet the main goal of a mid-stage clinical study, sending its shares down 32 percent in after-market trade.
|Pfizer Inc. (PFE.N)||$31.17||-0.05|
|GlaxoSmithKline plc (GSK.L)||1,592.50p||-6.00|
|Eli Lilly & Co. (LLY.N)||$49.86||+0.08|
|Forest Laboratories, Inc. (FRX.N)||$56.00||-0.44|
|Sanofi SA (SASY.PA)||€74.92||+0.11|
|Takeda Pharmaceutical Company Limited (4502.T)||¥5,000||-40.00|
|Transcept Pharmaceuticals Inc (TSPT.OQ)||$3.49||-0.01|
|Dainippon Sumitomo Pharma Co., Ltd. (4506.T)||¥1,456||-19.00|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Provider: S&P Capital IQ – STARS Reports
Provider: Pechala's Reports
Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of NEUROCRINE BIOSCIENCES INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.
Provider: Jefferson Research
Provider: Ford Investor Services, Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.